[Multiple sclerosis. Biomarkers for deciding treatment].
Meinl
E
E
Institut für Klinische Neuroimmunologie, Klinikum Grosshadern der LMU München.
Voltz
R
R
D051017:Apoptosis Regulatory Proteins; D001323:Autoantibodies / Q000097:blood*; D015415:Biomarkers / Q000097:blood*; D001921:Brain / Q000276:immunology / Q000473:pathology; D019204:GTP-Binding Proteins / Q000276:immunology; D006801:Humans; D016899:Interferon-beta / Q000009:adverse effects / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D008562:Membrane Glycoproteins / Q000235:genetics; D009103:Multiple Sclerosis / Q000175:diagnosis* / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D004676:Myelin Basic Protein / Q000276:immunology; D009185:Myelin Proteins; D018992:Myelin-Associated Glycoprotein / Q000276:immunology; D063308:Myelin-Oligodendrocyte Glycoprotein; D064547:Myxovirus Resistance Proteins; D009500:Neutralization Tests; D011379:Prognosis; D053221:TNF-Related Apoptosis-Inducing Ligand; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics
D051017:Apoptosis Regulatory Proteins; D001323:Autoantibodies; D015415:Biomarkers; C571326:MOG protein, human; D008562:Membrane Glycoproteins; D004676:Myelin Basic Protein; D009185:Myelin Proteins; D018992:Myelin-Associated Glycoprotein; D063308:Myelin-Oligodendrocyte Glycoprotein; D064547:Myxovirus Resistance Proteins; D053221:TNF-Related Apoptosis-Inducing Ligand; C505653:TNFSF10 protein, human; D014409:Tumor Necrosis Factor-alpha; D016899:Interferon-beta; D019204:GTP-Binding Proteins
Biomarker in der Therapie der Multiplen Sklerose. Lässt sich der Erfolg bald vorhersagen?